Lantern Pharma (LTRN): Net earnings per share growth forecast for next year

LTRN (Lantern) - company brandmark

Lantern Pharma Inc. (LTRN) is implementing the RADR AI platform to optimize oncology drug development and biomarker discovery. This chart from the GURU.Markets terminal illustrates the trend of consensus EPS forecasts for the coming year, where -23.50 represents today's metric value. RADR's digital simulations replace routine testing, while current financial stability is maintained through the systematic utilization of existing cash reserves.

Lantern Pharma Inc (LTRN): Net earnings per share growth forecast for next year from 07/04/2022 to 11/16/2026

Analytical breakdowns for Lantern Pharma Inc. (LTRN)

- share price and consensus valuation forecast:
Fundamental valuation:Lantern Pharma Inc., LTRN
Core merchandise of Lantern

Lantern Pharma Inc. (LTRN) utilizes the RADR AI platform to revive oncology drugs, creating value through unique genomic markers. This indicator reflects the investment bank consensus forecast for the percentage change in earnings per share (EPS) for the coming year. By analyzing the target EPS growth rate, an investor determines whether the market is pricing in the commercial success of the company's patents or perceives risks of valuation overheating.